Johannes H Schulte

Summary

Country: Germany

Publications

  1. pmc BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
    Anton Henssen
    Istituto Superiore di Sanita, Rome, Italy
    Oncotarget 4:2080-95. 2013
  2. ncbi request reprint MYCN regulates oncogenic MicroRNAs in neuroblastoma
    Johannes H Schulte
    Department of Pediatric Oncology and Haematology, University Children s Hospital Essen, Essen, Germany
    Int J Cancer 122:699-704. 2008
  3. doi request reprint Accurate prediction of neuroblastoma outcome based on miRNA expression profiles
    Johannes H Schulte
    University Children s Hospital Essen, Hufelandstr 55, 45122 Essen, Germany
    Int J Cancer 127:2374-85. 2010
  4. doi request reprint MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A
    Kristina Althoff
    Department of Pediatric Oncology and Hematology, University Children s Hospital Essen, Essen, Germany
    Int J Cancer 133:1064-73. 2013
  5. doi request reprint Transcription factor AP2alpha (TFAP2a) regulates differentiation and proliferation of neuroblastoma cells
    Johannes H Schulte
    Department of Pediatric Oncology and Hematology, University Children s Hospital Essen, Essen, Germany
    Cancer Lett 271:56-63. 2008
  6. pmc Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma
    Johannes H Schulte
    University Children s Hospital Essen, Hufelandstr 55, 45122 Essen, Germany
    Nucleic Acids Res 38:5919-28. 2010
  7. ncbi request reprint Reanalysis of neuroblastoma expression profiling data using improved methodology and extended follow-up increases validity of outcome prediction
    Alexander Schramm
    Department of Pediatric Oncology and Haematology, University Children s Hospital Essen, Hufelandstrasse 55, Essen, Germany
    Cancer Lett 282:55-62. 2009
  8. doi request reprint Expression of the TrkA or TrkB receptor tyrosine kinase alters the double-strand break (DSB) repair capacity of SY5Y neuroblastoma cells
    Johannes H Schulte
    Division of Oncology, University Children s Hospital of Essen, Hufelandstrasse 55, Essen, Germany
    DNA Repair (Amst) 7:1757-64. 2008
  9. doi request reprint MicroRNAs in the pathogenesis of neuroblastoma
    Johannes H Schulte
    Department of Pediatric Oncology and Haematology, University Children s Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany
    Cancer Lett 274:10-5. 2009
  10. pmc Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas
    Annette Künkele
    University Children s Hospital Essen, Pediatric Oncology, Essen, Germany
    Neuro Oncol 14:859-69. 2012

Collaborators

Detail Information

Publications22

  1. pmc BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
    Anton Henssen
    Istituto Superiore di Sanita, Rome, Italy
    Oncotarget 4:2080-95. 2013
    ..Our preclinical data provide evidence to pursue testing BET inhibitors, such as JQ1, as molecular targeted therapeutic options for patients with high-risk medulloblastomas overexpressing MYC or harboring MYC amplifications. ..
  2. ncbi request reprint MYCN regulates oncogenic MicroRNAs in neuroblastoma
    Johannes H Schulte
    Department of Pediatric Oncology and Haematology, University Children s Hospital Essen, Essen, Germany
    Int J Cancer 122:699-704. 2008
    ..We present evidence of miRNA dysregulation in neuroblastoma. Additionally, we report miRNA induction to be a new mechanism of gene expression downregulation by MYCN...
  3. doi request reprint Accurate prediction of neuroblastoma outcome based on miRNA expression profiles
    Johannes H Schulte
    University Children s Hospital Essen, Hufelandstr 55, 45122 Essen, Germany
    Int J Cancer 127:2374-85. 2010
    ..Specific miRNAs (e.g., miR-542-5p) might be important in neuroblastoma tumour biology, and qualify as potential therapeutic targets...
  4. doi request reprint MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A
    Kristina Althoff
    Department of Pediatric Oncology and Hematology, University Children s Hospital Essen, Essen, Germany
    Int J Cancer 133:1064-73. 2013
    ..Therapeutic strategies to re-express miR-137 in neuroblastomas could be useful to reduce tumor aggressiveness. ..
  5. doi request reprint Transcription factor AP2alpha (TFAP2a) regulates differentiation and proliferation of neuroblastoma cells
    Johannes H Schulte
    Department of Pediatric Oncology and Hematology, University Children s Hospital Essen, Essen, Germany
    Cancer Lett 271:56-63. 2008
    ....
  6. pmc Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma
    Johannes H Schulte
    University Children s Hospital Essen, Hufelandstr 55, 45122 Essen, Germany
    Nucleic Acids Res 38:5919-28. 2010
    ..In-depth sequence analysis revealed extensive post-transcriptional miRNA editing. Of 13 identified novel miRNAs, three were further analyzed, and expression could be confirmed in a cohort of 70 NBs...
  7. ncbi request reprint Reanalysis of neuroblastoma expression profiling data using improved methodology and extended follow-up increases validity of outcome prediction
    Alexander Schramm
    Department of Pediatric Oncology and Haematology, University Children s Hospital Essen, Hufelandstrasse 55, Essen, Germany
    Cancer Lett 282:55-62. 2009
    ....
  8. doi request reprint Expression of the TrkA or TrkB receptor tyrosine kinase alters the double-strand break (DSB) repair capacity of SY5Y neuroblastoma cells
    Johannes H Schulte
    Division of Oncology, University Children s Hospital of Essen, Hufelandstrasse 55, Essen, Germany
    DNA Repair (Amst) 7:1757-64. 2008
    ..Our data provide the first evidence for a functional relationship between tyrosine kinase receptor signaling and NHEJ-mediated DSB repair in cancer cells, potentially contributing to their genomic stability...
  9. doi request reprint MicroRNAs in the pathogenesis of neuroblastoma
    Johannes H Schulte
    Department of Pediatric Oncology and Haematology, University Children s Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany
    Cancer Lett 274:10-5. 2009
    ..Here we review the most recent attempts aiming to analyze the functional roles of microRNAs in neuroblastoma, the most devastating solid tumor in childhood...
  10. pmc Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas
    Annette Künkele
    University Children s Hospital Essen, Pediatric Oncology, Essen, Germany
    Neuro Oncol 14:859-69. 2012
    ..We suggest that inhibition of the MDM2-p53 interaction with nutlin-3 is a promising therapeutic option for medulloblastomas with functional p53 that should be further evaluated in clinical trials...
  11. ncbi request reprint Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy
    Johannes H Schulte
    Department of Paediatric Oncology and Hematology, University Children s Hospital Essen, Germany
    Cancer Res 69:2065-71. 2009
    ..We show that inhibition of LSD1 reprograms the transcriptome of neuroblastoma cells and inhibits neuroblastoma xenograft growth. Our results suggest that targeting histone demethylases may provide a novel option for cancer therapy...
  12. doi request reprint Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma
    Alexander Schramm
    Department of Pediatric Hematology and Oncology, University Children s Hospital, Essen, Germany
    Int J Cancer 132:E106-15. 2013
    ..As our results suggest MYCN involvement in mTOR pathway activation on the transcriptional level, mTOR inhibitors should be further evaluated for the treatment of MYCN-amplified neuroblastoma...
  13. pmc The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia
    Annette Künkele
    Department of Pediatric Hematology Oncology, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany
    BMC Cancer 13:452. 2013
    ..We investigated its usefulness as a marker for treatment stratification for children with ALL...
  14. doi request reprint The low-affinity neurotrophin receptor, p75, is upregulated in ganglioneuroblastoma/ganglioneuroma and reduces tumorigenicity of neuroblastoma cells in vivo
    Johannes H Schulte
    Department of Pediatric Oncology and Haematology, University Children s Hospital Essen, 45122 Essen, Germany
    Int J Cancer 124:2488-94. 2009
    ....
  15. ncbi request reprint Translating expression profiling into a clinically feasible test to predict neuroblastoma outcome
    Alexander Schramm
    Division of Hematology and Oncology, University Children s Hospital Essen, Essen, Germany
    Clin Cancer Res 13:1459-65. 2007
    ..To assess the feasibility of predicting neuroblastoma outcome using highly parallel quantitative real-time PCR data...
  16. pmc The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma
    Kristian W Pajtler
    Department of Pediatric Oncology and Hematology, University Hospital Essen, Essen, Germany
    Acta Neuropathol Commun 1:19. 2013
    ..Hypomethylation of lysine 4 in histone 3 (H3K4) is also associated with a dismal prognosis for medulloblastoma patients. Functional characterization of important epigenetic key regulators is urgently needed...
  17. doi request reprint Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre
    Annette Künkele
    Department of Paediatric Oncology and Haematology, University Hospital Essen, Essen, Germany
    Br J Ophthalmol 97:1277-83. 2013
    ..We assessed a new chemoreduction protocol using intravenous cyclophosphamide with reduced dose of carboplatin on eye retention in patients with retinoblastoma...
  18. doi request reprint Long-term follow-up of pediatric patients receiving total body irradiation before hematopoietic stem cell transplantation and post-transplant survival of >2 years
    Annette Künkele
    Department of Pediatric Hematology Oncology, Pediatrics III, University Duisburg Essen, Essen, Germany
    Pediatr Blood Cancer 60:1792-7. 2013
    ..The radiation dose is limited by its toxicity to healthy organs. Many reports describe long-term sequelae from TBI in adults, but comparable data for pediatric patients are scarce...
  19. ncbi request reprint Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling
    Alexander Schramm
    Department of Pediatric Oncology and Hematology, University Hospital of Essen, Hufelandstr 55, Essen 45122, Germany
    Oncogene 24:7902-12. 2005
    ..Our data suggest that microarray-derived data in addition to traditional clinical factors will be useful for risk assessment and defining biological properties of neuroblastoma...
  20. ncbi request reprint The neurotrophin receptor TrkB cooperates with c-Met in enhancing neuroblastoma invasiveness
    Monica Hecht
    Department of Pediatrics, University of Goettingen, Germany
    Carcinogenesis 26:2105-15. 2005
    ..We conclude that TrkB expression in neuroblastoma cells results in an increase in their invasive capability via upregulated expression of HGF/c-Met and enhanced activity of proteolytic networks...
  21. ncbi request reprint Biological effects of TrkA and TrkB receptor signaling in neuroblastoma
    Alexander Schramm
    Division of Hematology Oncology and Endocrinology, University Children s Hospital of Essen, Hufelandstrasse 55, 45122 Essen, Germany
    Cancer Lett 228:143-53. 2005
    ..This short review discusses recent data on the biological roles of TrkA and TrkB signaling in neuroblastoma...
  22. ncbi request reprint Microarray analysis reveals differential gene expression patterns and regulation of single target genes contributing to the opposing phenotype of TrkA- and TrkB-expressing neuroblastomas
    Johannes H Schulte
    University Children s Hospital of Essen, Germany
    Oncogene 24:165-77. 2005
    ..Fine-tuning of the malignant phenotype may be achieved by additional ligand stimulation with subsequent activation of a few specific genes...